UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8+ T Cells in Hepatocellular Carcinoma

Hepatology (Baltimore, Md.), 2020-03, Vol.71 (3), p.955-971

2020

Volltextzugriff (PDF)

Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study

Liver international, 2020-10, Vol.40 (10), p.2544-2552

2020

Volltextzugriff (PDF)

Adjuvant treatment for locally advanced gastric cancer: an Asian perspective

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024-05, Vol.27 (3), p.439-450

2024

Volltextzugriff (PDF)

Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment

Scientific reports, 2022-01, Vol.12 (1), p.1678-1678, Article 1678

2022

Volltextzugriff (PDF)

Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib

International journal of cancer, 2022-11, Vol.151 (10), p.1770-1777

2022

Volltextzugriff (PDF)

SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024-09, Vol.27 (5), p.1147-1152

2024

Volltextzugriff (PDF)

Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022-01, Vol.25 (1), p.170-179

2022

Volltextzugriff (PDF)

Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024, Vol.27 (4), p.811-818

2024

Volltextzugriff (PDF)

Immunological and clinical implications of immune checkpoint blockade in human cancer

Archives of Pharmacal Research, 2019, 42(7), , pp.567-581

2019

Volltextzugriff (PDF)

Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer

Scientific reports, 2023-11, Vol.13 (1), p.20047-20047, Article 20047

2023

Volltextzugriff (PDF)

Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2023-07, Vol.26 (4), p.604-613

2023

Volltextzugriff (PDF)

Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022-07, Vol.25 (4), p.794-803

2022

Volltextzugriff (PDF)

Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis

Liver international, 2021-06, Vol.41 (6), p.1389-1397

2021

Volltextzugriff (PDF)

Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine–platinum doublet plus trastuzumab

Cancer Immunology, Immunotherapy, 2022-04, Vol.71 (4), p.829-838

2022

Volltextzugriff (PDF)

Insertion–deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022, Vol.25 (1), p.226-234

2022

Volltextzugriff (PDF)

Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024-07, Vol.27 (4), p.819-826

2024

Volltextzugriff (PDF)

Clinical outcomes of Epstein–Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024, Vol.27 (1), p.146-154

2024

Volltextzugriff (PDF)

A prognostic index for extranodal marginal‐zone lymphoma based on the mucosa‐associated lymphoid tissue International Prognostic Index and serum β2‐microglobulin levels

British journal of haematology, 2021-04, Vol.193 (2), p.307-315

2021

Volltextzugriff (PDF)

Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024, Vol.27 (4), p.884-885

2024

Volltextzugriff (PDF)

Implication of CD69+CD103+ tissue‐resident‐like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma

Liver international, 2021-04, Vol.41 (4), p.764-776

2021

Volltextzugriff (PDF)

Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2022-11, Vol.25 (6), p.1039-1049

2022

Volltextzugriff (PDF)

PD-1 blockade-unresponsive human tumor-infiltrating CD8 + T cells are marked by loss of CD28 expression and rescued by IL-15

Cellular & molecular immunology, 2021-02, Vol.18 (2), p.385-397

2021

Volltextzugriff (PDF)

Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib

Hepatology research, 2021-07, Vol.51 (7), p.796-802

2021

Volltextzugriff (PDF)

Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients

Scientific reports, 2020-08, Vol.10 (1), p.14293-14293, Article 14293

2020

Volltextzugriff (PDF)

DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2024, Vol.27 (1), p.110-117

2024

Volltextzugriff (PDF)

1 – 25 von 258

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(210)
Mit Volltextzugriff
(190)

Publikationsform

Sprache

Englisch
(226)
Koreanisch
(30)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8+ T Cells in Hepatocellular Carcinoma

Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study

Adjuvant treatment for locally advanced gastric cancer: an Asian perspective

Dynamic increase of M2 macrophages is associated with disease progression of colorectal cancers following cetuximab-based treatment

Clinical outcomes and prognostic factors for patients with high‐risk gastrointestinal stromal tumors treated with 3‐year adjuvant imatinib

SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review

Radiological criteria for selecting candidates for neoadjuvant chemotherapy for gastric cancer: an exploratory analysis from the PRODIGY study

Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer

Immunological and clinical implications of immune checkpoint blockade in human cancer

Clinicopathologic features and prognostic value of claudin 18.2 overexpression in patients with resectable gastric cancer

Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions

Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab

Lenvatinib versus sorafenib in first‐line treatment of unresectable hepatocellular carcinoma: An inverse probability of treatment weighting analysis

Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine–platinum doublet plus trastuzumab

Insertion–deletion rate is a qualitative aspect of the tumor mutation burden associated with the clinical outcomes of gastric cancer patients treated with nivolumab

Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy

Clinical outcomes of Epstein–Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy

A prognostic index for extranodal marginal‐zone lymphoma based on the mucosa‐associated lymphoid tissue International Prognostic Index and serum β2‐microglobulin levels

Letter to the editor: 5-year follow-up results of a JCOG1104 (OPAS-1) phase III non-inferiority trial to compare 4 courses and 8 courses of S-1 adjuvant chemotherapy for pathological stage II gastric cancer

Implication of CD69+CD103+ tissue‐resident‐like CD8+ T cells as a potential immunotherapeutic target for cholangiocarcinoma

Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study

PD-1 blockade-unresponsive human tumor-infiltrating CD8 + T cells are marked by loss of CD28 expression and rescued by IL-15

Role of the prognostic nutritional index in predicting survival in advanced hepatocellular carcinoma treated with regorafenib

Distinct tumor immune microenvironments in primary and metastatic lesions in gastric cancer patients

DNA mismatch repair deficiency and outcomes of patients with locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery plus postoperative S-1: a sub-analysis of the phase 3 PRODIGY trial

Suchergebnisse filtern